Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Acorda Therapeutics Inc. ACOR

Acorda Therapeutics Inc is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.


Recent & Breaking News (NDAQ:ACOR)

Acorda Data on Inhaled Levodopa Therapy CVT-301 Recognized in Blue Ribbon Highlights Session at International Congress of Parkinson's Disease and Movement Disorders

Business Wire June 24, 2015

Acorda Presents Data on Inhaled Levodopa Therapy CVT-301 at International Congress of Parkinson's Disease and Movement Disorders

Business Wire June 16, 2015

Acorda CEO Ron Cohen Named BIO Chairman for 2015-2016 Term

Business Wire June 15, 2015

Acorda Therapeutics to Present at the Jefferies Global Healthcare Conference

Business Wire May 26, 2015

Acorda Therapeutics to Present at the Bank of America Merrill Lynch 2015 Health Care Conference

Business Wire May 5, 2015

Acorda Therapeutics to Present at the Deutsche Bank 40th Annual Health Care Conference

Business Wire May 1, 2015

Acorda Reports First Quarter 2015 Financial Results

Business Wire April 30, 2015

Acorda Therapeutics to Host Conference Call to Discuss First Quarter 2015 Financial Results on April 30, 2015

Business Wire April 23, 2015

Acorda Presents Data on First Clinical Study of Remyelinating Antibody for Multiple Sclerosis at American Academy of Neurology Annual Meeting

Business Wire April 22, 2015

Acorda Therapeutics Named One of the Best Places to Work For in New York 2015

Business Wire April 22, 2015

Acorda Rings NASDAQ Opening Bell to Mark 20th Anniversary

Business Wire March 16, 2015

Acorda Therapeutics, Inc. (ACOR) to Ring The Nasdaq Stock Market Opening Bell

GlobeNewswire March 13, 2015

Acorda to Present New Analyses of Cimaglermin alfa (GGF2) Data at the 64th Annual ACC Scientific Session

Business Wire March 10, 2015

Acorda Therapeutics to Present at the Barclays Global Healthcare Conference

Business Wire March 4, 2015

Acorda Therapeutics to Present at the Cowen 35th Annual Health Care Conference

Business Wire February 23, 2015

Acorda Therapeutics to Present at the 2015 RBC Capital Markets' Healthcare Conference

Business Wire February 17, 2015

Acorda Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results

Business Wire February 12, 2015

Acorda Therapeutics to Present at the 2015 Leerink Global Healthcare Conference

Business Wire February 5, 2015

Acorda Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2014 Financial Results on February 12, 2015

Business Wire February 5, 2015

Acorda Announces Safety and Tolerability Data from First Clinical Trial of Remyelinating Antibody in Multiple Sclerosis

Business Wire February 2, 2015